A randomized trial to evaluate patients with RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR
Cancer - Lung
John McCann, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this study is to compare any good/bad effects patients may have when treated with standard treatment against patients who are treated with standard treatment plus erlotinib. You are being asked to take part in this research study because you have early stage non-small cell lung cancer that was surgically removed and may have been treated with chemotherapy and/or radiation. The tumor removed has a mutation of a gene called EGFR.
Completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.